Amarin Corporation Plc Loss Submission Form

(i) there was an increasingly high risk that certain of Amarin’s patents would be invalidated; (ii) once the District Court invalidated certain of Amarin’s patents, there was little to no chance of reversing that ruling; (iii) the Company’s litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing abbreviated new drug application litigation posed to the Company’s business and future prospects; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.